Press releases | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

26 Mar 2022

New Long-Term Complete Skin Clearance Data for BIMZELX[®]▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Read More
25 Mar 2022

Disposal of own shares

Read More
25 Mar 2022

New UCB data analysis adds to demonstrated efficacy of romosozumab▼ to reduce the risk of fractures

Read More
25 Mar 2022

WCO-IOF-ESCEO 2022 – Post-hoc analysis on the proportion of patients treated with EVENITY[® ]▼(romosozumab) reaching surrogate threshold effect that predicts fracture risk reduction

Read More
18 Mar 2022

Transparency notification FMR LLC

Read More
18 Mar 2022

Disposal of own shares

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe